FR941202-0-00031 FR941202-0-00001 (c) * * * (2) Patient's or human research subject's name, and identification number if one has been assigned; (3) Prescribed dosage and activity of the dosage at the time of measurement, or a notation that the total activity is less than 1.1 megabecquerels (30 microcuries); * * * * * 29. In §35.60, paragraphs (b) and (c) are revised to read as follows: §35.60 Syringe shields and labels. * * * * * (b) To identify its contents, a licensee shall conspicuously label each syringe or syringe radiation shield that contains a syringe with a radiopharmaceutical. The label must show the radiopharmaceutical name or its abbreviation, the clinical procedure to be performed, or the patient's or the human research subject's name. (c) A licensee shall require each individual who prepares a radiopharmaceutical kit to use a syringe radiation shield when preparing the kit and shall require each individual to use a syringe radiation shield when administering a radiopharmaceutical by injection unless the use of the shield is contraindicated for that patient or human research subject. 30. Section 35.75 is revised to read as follows: §35.75 Release of patients or human research subjects containing radiopharmaceuticals or permanent implants. (a) A licensee may not authorize release from confinement for medical care any patient or human research subject administered a radiopharmaceutical until either: (1) The measured dose rate from the patient or the human research subject is less than 5 millirems per hour at a distance of 1 meter; or (2) The activity in the patient or the human research subject is less than 30 millicuries. (b) A licensee may not authorize release from confinement for medical care of any patient or human research subject administered a permanent implant until the measured dose rate from the patient or the human research subject is less than 5 millirems per hour at a distance of 1 meter. 31. Section 35.100 is revised to read as follows: §35.100 Use of unsealed byproduct material for uptake, dilution, and excretion studies. A licensee may use for uptake, dilution, or excretion studies any unsealed byproduct material prepared for medical use that is either: (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in §35.920, or an individual under the supervision of either as specified in §35.25. 32. Section 35.200 is revised to read as follows: §35.200 Use of unsealed byproduct material for imaging and localization studies. A licensee may use for imaging and localization studies any unsealed byproduct material prepared for medical use that is either: (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in §35.920, or an individual under the supervision of either as specified in §35.25. 33. Section 35.300 is revised to read as follows: §35.300 Use of unsealed byproduct material for therapeutic administration. A licensee may use for therapeutic administration any unsealed byproduct material prepared for medical use that is either: (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in §35.920, or an individual under the supervision of either as specified in §35.25.
